Jyong Biotech holder reports 33.34% ownership stake
Rhea-AI Filing Summary
Jyong Biotech Ltd. received a major ownership disclosure showing that Perfect Minds Co., Ltd. and related entities beneficially own 25,349,500 ordinary shares, or 33.34% of the company’s ordinary shares, based on 76,027,667 shares outstanding as of April 24, 2026.
Perfect Minds, a Seychelles holding company, directly holds the shares. It is wholly owned by Innovation Global Group Limited, which in turn is owned by The Innovation Trust, for which Unity Trust Limited acts as trustee. Ms. Kuo Fu‑Feng, the issuer’s Chief Executive Officer and Chairwoman, is settlor of the trust and sole director of Perfect Minds and has sole voting and dispositive power over these shares.
The stake was acquired for approximately $5,760,075, funded by Ms. Kuo. The reporting persons state they hold the shares for investment purposes and, aside from what is described, do not currently have additional plans tied to corporate actions listed under Item 4.
Positive
- None.
Negative
- None.
Insights
CEO-linked trust structure controls about one-third of Jyong Biotech.
The filing shows entities associated with Ms. Kuo Fu‑Feng beneficially own 25,349,500 ordinary shares, representing 33.34% of Jyong Biotech. The shares are held through Perfect Minds Co., Ltd., its BVI parent Innovation Global Group Limited, and The Innovation Trust.
Although IGGL, The Innovation Trust and Unity Trust Limited report no voting power, Ms. Kuo has sole voting and dispositive power via Perfect Minds. This consolidates significant influence in one executive-linked holder, aligning management and ownership.
The stake was acquired for about $5,760,075, funded by Ms. Kuo, and is described as held for investment purposes. Future company filings may clarify if this ownership level changes over time or if any strategic transactions emerge involving this block.
Key Figures
Key Terms
beneficially own financial
sole dispositive power financial
pecuniary interest financial
family discretionary trust financial
Schedule 13D regulatory
FAQ
What percentage of Jyong Biotech (MENS) is held by the reporting group?
What is the relationship between Perfect Minds and Innovation Global Group in the Jyong Biotech (MENS) filing?
Does the Jyong Biotech (MENS) Schedule 13D state any specific corporate plans?
AI-generated analysis. How Rhea-AI works. Not financial advice.